Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2020 Mar 27;19(6):1266–1278. doi: 10.1158/1535-7163.MCT-19-0174

Figure 6. Effects of CBZ on the growth of SN12PM6 RCC in bone in vivo.

Figure 6.

A) BIGH3 mRNA levels in BIGH3-overexpressing SN12PM6 RCC cells (SN12PM6/BG) and its control SN12PM6/Vector cells were determined by real-time RT-PCR. B) Viability of cells in (A) over 5 days were determined by MTT assay. C) Cells in (A) were treated with CBZ at 0, 50 nM and 100 nM for 5 days, and cell viability was determined as in (B). The growth of SN12PM6/Vector (D) and SN12PM6/BG (E) RCC tumor cells in bone over 21 days after initiation of CBZ treatment was monitored by BLI and total flux values were used for BLI quantification. *: P < 0.05; **P < 0.01. F) Bone histomorphometry analysis of number of osteoblasts per osteoid perimeter (N. Ob/O.Pm), bone volume fraction (BV/TV%) and average trabecular thickness (Tb. Th) on Toluidine Blue stained bone sections. G) Bone histomorphometry analysis of blood vessel volume (BVV) and blood vessel surface (BVS) on Toluidine Blue stained bone sections. H) Bone histomorphometry analysis of number of osteoclasts (Oc Number), number osteoclasts per erosion perimeter (N. Oc/E. Pm), and number of osteoclasts per bone perimeter (N. Oc/B. Pm) on TRAP stained bone sections.